Previous close | 1.1250 |
Open | 1.1250 |
Bid | 1.1250 x N/A |
Ask | 1.1400 x N/A |
Day's range | 1.1250 - 1.1250 |
52-week range | 0.3300 - 1.3500 |
Volume | |
Avg. volume | 247,987 |
Market cap | 304.694M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1800 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.16 |
EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchronization Therapy (CRT) System.
EBR Systems, Inc. (ASX: "EBR", "EBR Systems", or the "Company"), developer of the world's only wireless cardiac pacing system for heart failure, is pleased to announce that the Company's WiSE® technology will be featured at the 15th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in Singapore from the 18th to the 20th of November.